ReviewCancers2020
Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer.
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 36 citations in OpenAlex.
- Isthmic papillary thyroid microcarcinoma: clinicopathological features and prognostic factors following isthmusectomy based on tumor size stratification.Discover oncology · 2026Article
- First successful radiofrequency ablation for papillary thyroid microcarcinoma in Indonesia: a case report.International journal of surgery case reports · 2026Article
- Evolving Practices in Low-Risk Papillary Thyroid Cancer: Impact of the 2015 ATA Guidelines.Current oncology (Toronto, Ont.) · 2026Article
- Predictive models for contralateral occult thyroid carcinoma and central lymph node metastasis in unilateral multifocal papillary thyroid carcinoma based on ultrasound.Quantitative imaging in medicine and surgery · 2026Article
- Papillary Thyroid Carcinoma and Its Hormonal Effects in Women Following Surgical Removal.Cureus · 2025Review
- Cancer-related Fear and Worry in Patients With Low-risk Thyroid Cancer: A Longitudinal Cohort Study.The Journal of clinical endocrinology and metabolism · 2025Article
- The Initial Risk Stratification System for Differentiated Thyroid Cancer: Key Updates in the 2024 Korean Thyroid Association Guideline.Endocrinology and metabolism (Seoul, Korea) · 2025Review
- Impact of the 2015 American Thyroid Association Guidelines on Treatment of Low-Risk Thyroid Cancer.Laryngoscope investigative otolaryngology · 2025Article
- Construction of predictive models for contralateral occult thyroid carcinoma and central lymph node metastasis in unilateral papillary thyroid carcinoma using machine learning.Frontiers in oncology · 2025Article
- Central Neck Dissection in Papillary Thyroid Carcinoma: Benefits and Doubts in the Era of Thyroid Lobectomy.Biomedicines · 2024Article
- Current practice in intermediate risk differentiated thyroid cancer - a review.Reviews in endocrine & metabolic disorders · 2024Review
- Article
- The proposed modification of TNM staging and therapeutic strategy for skip metastasis in papillary thyroid carcinoma: A multicenter retrospective cohort study.Cancer medicine · 2023Article
- Ultrasound grayscale ratio: a reliable parameter for differentiating between papillary thyroid microcarcinoma and micronodular goiter.BMC endocrine disorders · 2022Article
- Review
- Optimal Surgical Extent in Patients with Unilateral Multifocal Papillary Thyroid Carcinoma.Cancers · 2022Article
- Preoperative Ultrasonography in the Evaluation of Suspected Familial Non-Medullary Thyroid Cancer: Are We Able to Predict Multifocality and Extrathyroidal Extension?Journal of clinical medicine · 2021Article
- Should Contralateral Nodules Be an Indication of Total or Completion Thyroidectomy for Patients With Unilateral Papillary Thyroid Carcinoma?Frontiers in endocrinology · 2021Article
- The role of neck ultrasound in the follow-up of low- and intermediate- risk papillary thyroid cancer.Archives of endocrinology and metabolismArticle
- Treatment strategies for low-risk papillary thyroid carcinoma: a position statement from the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism (SBEM).Archives of endocrinology and metabolismArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many recent publications and guidelines have promoted a "more is less" approach in terms of treatment for low to intermediate risk differentiated thyroid cancer (DTC), which comprise the vast majority of thyroid cancers: less extensive surgery, less radioactive iodine, less or no thyroid hormone suppression, and less frequent or stringent follow-up. Following this approach, thyroid lobectomy has been proposed as a means of decreasing short- and long-term postoperative morbidity while maintaining an excellent prognosis for tumors meeting specific macroscopic and microscopic criteria. This article will examine the pros and cons of thyroid lobectomy for low to intermediate risk cancers and discuss, in detail, criteria for patient selection and oncological outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.